GlassScriptPhysician profile
Derrick Richardson
NPI 1992727150
$8,150.36
in general payments reported to CMS, 2019-2025
28 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $813 · 2021: $1,535 · 2022: $1,278 · 2023: $1,101 · 2024: $957 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.32 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,187.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,633.69 | 2019-2025 | Trulance, Xifaxan, Uceris |
| Gilead Sciences, INC. | $1,108.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $906.38 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Pfizer INC. | $562.59 | 2019-2025 | |
| Janssen Biotech, INC. | $554.47 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $204.05 | 2022-2025 | |
| Braintree Laboratories, INC. | $168.29 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $132.77 | 2021-2023 | |
| Celgene Corporation | $93.01 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $78.85 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $76.96 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $62.05 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $49.35 | 2019-2022 | |
| Amgen INC. | $47.74 | 2021-2023 | Avsola, Amjevita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $45.55 | 2019 | |
| Lilly USA, LLC | $33.61 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $29.60 | 2019 | |
| Medtronic, INC. | $28.72 | 2023 | Interstim |
| Celltrion USA INC. | $27.00 | 2025 | Vegzelma |
| Qol Medical, LLC | $25.28 | 2025 | Sucraid |
| Ardelyx, INC. | $15.81 | 2022 | |
| Novo Nordisk INC | $14.71 | 2025 | Wegovy |
| Sandoz INC. | $14.36 | 2023 | Hyrimoz |
| Ucb, INC. | $13.68 | 2019 | |
| Medtronic USA, INC. | $13.09 | 2019 | |
| Neurocrine Biosciences, INC. | $11.73 | 2022 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.